Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02526511 · ClinicalTrials.gov registry record · NA
Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
NCT02526511 is a NA study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 75 participants.
The verdict
NCT02526511, a NA study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
Study Summary
This pilot clinical trial studies perfusion magnetic resonance imaging in diagnosing patients with kidney tumors. Diagnostic procedures, such as perfusion magnetic resonance imaging, may help find and diagnose kidney tumors and predict and monitor a patient's response to treatment.
Interventions
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- PROCEDURE Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- PROCEDURE Perfusion Magnetic Resonance Imaging
- PROCEDURE Arterial Spin Labeling Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2015-04 |
| Est. Completion | 2023-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02526511
The ClinicalTrials.gov registry entry for NCT02526511 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dynamic Contrast-Enhanced Magnetic Resonance Imaging is the first listed.
NCT02526511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02526511 about?
NCT02526511 is a clinical study titled "Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors". This pilot clinical trial studies perfusion magnetic resonance imaging in diagnosing patients with kidney tumors. Diagnostic procedures, such as perfusion magnetic resonance imaging, may help find and diagnose kidney tumors and predict and monitor a patient's response to treatment.
What is the current status of trial NCT02526511?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2015-04. Estimated completion is 2023-09.
What interventions are being tested in trial NCT02526511?
The interventions under investigation include: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), Perfusion Magnetic Resonance Imaging (PROCEDURE), Arterial Spin Labeling Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT02526511?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.